Navigation Links
ArunA Biomedical Announces Commercial Release of its Human Embryonic Stem Cell Derived Mesenchymal Cells
Date:3/27/2009

ATHENS, Ga., March 27 /PRNewswire/ -- ArunA Biomedical, Inc., announced today that it will make its CELL-EZ(TM) brand hMC(TM) human mesenchymal progenitor cells commercially available to the research community in mid 2009. Derived from pluripotent human embryonic stem cells, ArunA's hMC lines will offer unique, highly proliferative uniform populations of mesenchymal cells in a feeder free monolayer culture.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080819/CLTU003LOGO)

The introduction of our CELL-EZ hMC(TM) cell lines is a significant step forward for stem cell research." Dr. Steven Stice, ArunA CSO and Co-Founder commented, "CELL-EZ hMC(TM) will provide a human cell based format for a wide range of research in areas from osteogenisis to cancer research. Unlike human bone marrow and other tissue derived mesenchymal cells, ArunA's hMC cells have the unique ability to differentiate into osteoblasts and chondrocytes but not adipocytes, making them a unique tool for research and drug discovery directed at areas such as Osteoporosis."

The CELL-EZ hMC(TM) cell lines were further developed by ArunA through a technology license agreement with the University of Georgia using a proprietary platform technology for producing progenitor cells from pluripotent stem cells. The CELL-EZ hMC(TM) cell lines are from a stable genetic background and can be genetically modified to produce constant and more informative research results. This product line compliments ArunA's portfolio of pluripotent stem cell products derived from human embryonic stem cells.

About ArunA Biomedical

Located in Athens, Georgia, ArunA Biomedical, Inc. is a privately held biotechnology corporation dedicated to the discovery, manufacturing and commercialization of emerging new technologies in human embryonic stem cell research for use in drug discovery and basic research. ArunA is the first company to commercialize products derived from human embryonic stem cells and sees its proprietary technology as a catalyst leading to the discovery of novel therapeutic compounds, tests for neurotoxicity and breakthroughs in understanding human development and diseases such as Parkinson's, Alzheimer's, Huntington's and cancer.

For more information, visit: www.ArunAbiomedical.com.

This press release contains forward-looking statements regarding the company's potential impact on scientific research. Certain conditions could alter the outcome or progress of these statements including but not limited to unexpected manufacturing issues, product performance and quality control/assurance issues. Forward- looking statements are based on the opinions, beliefs and expectations of the company or individuals quoted in the press release and the company does not assume any obligation to update these forward-looking statements if circumstances change.


'/>"/>
SOURCE ArunA Biomedical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. ArunA Biomedical Names William T. Sharp President and Chief Executive Officer
2. ArunA Biomedical Announces Exclusive Worldwide Technology Licensing Agreement to Commercialize Human Embryonic Stem Cell Derived Mesenchymal Cells
3. ArunA Biomedical Announces Commercial Release of its Human Embryonic Stem Cell Derived Neural Cells
4. ArunA Biomedical, Inc. Announces Alliance with Neuromics for Distribution of Normal Human Neural Cells
5. Serica Technologies Expands Facilities in Massachusetts, Combines State-Of-The-Art Textile Engineering and Biomedical Manufacturing
6. CryoLife Signs Distribution Agreement for Inclusion of BioGlue(R) Surgical Adhesive in Hernia Repair Kit with Proxy Biomedical Surgical Meshes
7. Verax Biomedical Receives 510 (k) Clearance from FDA for Platelet PGD Test
8. SLIM Search, Inc. Sponsors Next Generation Sequencing Conference for the Biomedical Market
9. NCIIA Announces Launch of 4th Annual Student Biomedical Innovation Competition
10. New Scientists Boost Disease-based Research at Boston Biomedical Research Institute
11. Foundation for Biomedical Research Board Chairman Awarded Congressional Gold Medal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... 2016 , ... Cancer experts from Austria, Hungary, Switzerland, and ... new and helpful biomarker for malignant pleural mesothelioma. Surviving Mesothelioma has just published ... , Biomarkers are components in the blood, tissue or body fluids that ...
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... announced the funding of a Sponsored Research Agreement ... circulating tumor cells (CTCs) from cancer patients.  The ... in CTC levels correlate with clinical outcomes in ... These data will then be employed to support ...
(Date:6/24/2016)... ... 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers use ... 6000i models are higher end machines that use the more unconventional z-dimension of 20mm. ... from the bottom of the cuvette holder. , FireflySci has developed several Agilent ...
(Date:6/23/2016)... CAMBRIDGE, Mass. , June 23, 2016 /PRNewswire/ ... the development of novel compounds designed to target ... compound, napabucasin, has been granted Orphan Drug Designation ... in the treatment of gastric cancer, including gastroesophageal ... cancer stemness inhibitor designed to inhibit cancer stemness ...
Breaking Biology Technology:
(Date:5/3/2016)... VILNIUS, Lithuania , May 3, 2016 /PRNewswire/ ... today released the MegaMatcher Automated Biometric Identification ... deployment of large-scale multi-biometric projects. MegaMatcher ABIS can ... and accuracy using any combination of fingerprint, face ... of MegaMatcher SDK and MegaMatcher ...
(Date:4/26/2016)... , April 27, 2016 ... the  "Global Multi-modal Biometrics Market 2016-2020"  report to ... ) , The analysts forecast the ... CAGR of 15.49% during the period 2016-2020.  ... number of sectors such as the healthcare, BFSI, ...
(Date:4/14/2016)... 14, 2016 BioCatch ™, ... today announced the appointment of Eyal Goldwerger ... Goldwerger,s leadership appointment comes at a time ... the deployment of its platform at several of the ... which discerns unique cognitive and physiological factors, is a ...
Breaking Biology News(10 mins):